Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3295 | Recombinant new coronavirus vaccine (CHO cells) high-dose group Wiki | 0.71 |
| drug3296 | Recombinant new coronavirus vaccine (CHO cells) placebo group Wiki | 0.71 |
| drug3294 | Recombinant new coronavirus vaccine (CHO cell) low-dose group Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS). Severe patients can require access to intensive care unit (ICU). Early rehabilitation is known to be effective in critically ill patients and in ARDS. The role of respiratory physiotherapy in critical COVID-19 patients is still unclear. The aim of this study is to describe the bundle and the timing of respiratory physiotherapy used with severe COVID-19 patients from ICU to hospital discharge. Functional condition of patients at discharge will be assessed and described.
Description: Total number of physiotherapy treatments performed on patients during hospitalization
Measure: Number of physiotherapy treatments Time: Through study completion, an average of 60 daysDescription: Number of each activity performed on patients among early mobilization, positioning, Uso of non invasive ventilation (NIV) and/or continuous positive airway pressure (CPAP), oxygen titration, airway clearance.
Measure: Type of physiotherapy treatments Time: Through study completion, an average of 60 daysDescription: Median number of days from patients intubation to the first physiotherapy treatment
Measure: Time of the first physiotherapy treatment Time: From patient intubation to first time patient was treated by a physiotherapist; up to 60 daysDescription: Median number of days from patients intubation to standing
Measure: First time standing Time: From patient intubation to first time standing; up to 60 daysDescription: Median number of days from patients intubation to walking
Measure: First time walking Time: From patient intubation to first time walking; up to 60 daysDescription: Median number of days from patients intubation to sitting out of bed
Measure: First time sitting out of bed Time: From patient intubation to first time sitting out of bed; up to 60 daysDescription: Median distance (metres) obtained at the 6MWT
Measure: 6 minutes walking test (6MWT) Time: Assessed when patients are discharged from the hospital; up to 60 daysDescription: Median number of sit-to-stand repetitions obtained
Measure: 1 minute sit-to-stand test (1m-STST) Time: Assessed when patients are discharged from the hospital; up to 60 daysDescription: Median upper extremity muscle strength measured by the Medical Research Council sum score (MRC-SS). The muscle scale grades muscle power on a scale of 0 (no visible muscle contraction) to 5 (active movement against full resistance). The movement tested are wrist flexion, forearm flexion and shoulder abduction.
Measure: Upper extremity muscles strength Time: Assessed at 2 time points, when patients are discharged from ICU and when patients are discharged from the hospital; up to 60 days.Description: Median lower extremity muscle strength measured by the Medical Research Council sum score (MRC-SS). The muscle scale grades muscle power on a scale of 0 (no visible muscle contraction) to 5 (active movement against full resistance). The movement tested are ankle dorsiflexion, knee extension and hip flexion.
Measure: Lower extremity muscles strength Time: Assessed at 2 time points, when patients are discharged from ICU and when patients are discharged from the hospital; up to 60 days.Description: Median score obtained th the Barthel Index for Activities of Daily Living (ADL). The Barthel Index measures functional independence in ADL. Scores range from 0 to 100, with higher scores indicating greater independence in ADL.
Measure: Functional independence in ADL Time: Assessed when the patient is discharged from the hospital; up to 60 days.Description: Mean number of days patients stayed in ICU
Measure: ICU stay length Time: From ICU admission to ICU discharge; up to 60 days.Description: Mean number of days patients stayed at the hospital
Measure: Length of hospitalization Time: From hospital admission to hospital discharge; up to 60 days.Description: Mean number of days patients were invasively mechanically ventilated
Measure: Duration of invasive mechanical ventilation (IMV) Time: From first day patient are mechanically ventilated to IMV stop; up to 60 days.Description: Number of patients that following hospital discharge returned home
Measure: Patients returned home Time: Up to 60 days.Description: Number of patients that were discharged from acute hospital to in-patient rehabilitation
Measure: Patients discharged to in-patient rehabilitation Time: Up to 60 days.Description: Number of patients that following hospital discharge were transferred to other hospitals
Measure: Patients transferred to other hospitals Time: Up to 60 days.Description: Number of patients that died from any cause during hospitalization
Measure: Exitus Time: From ICU admission until date of death from any cause, assessed up to 60 days.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports